ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2175 entries already.
As resource-poor biotech start-ups are the drivers of innovation in the biotech sector, partnering with Big Pharma is essential to survive in a competitive environment. Yet, how to do most effectively? The most often held pharma partnering conference worldwide, euroPLX, provides a plausible answer.
Krakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer.
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
US-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO.
The EU’s Big Pharma companies have sharply criticised the European Parliament’s Legal Committee JURI backing of an amended proposal of the European Commission (EC) to introduce a supplementary protection certificates (SPC) manufacturing waiver. Under the waiver, EU-based biosimilar and generics makers would be allowed to export copycat drugs during the SPC period that adds five years of additional IP protection to the 20 years of patent duration.
A research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.
Pfizer Inc has paid €45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
After positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate a global Phase III study with its autologous cell-based immunotherapy also in this indication.